vTv Therapeutics Inc. (VTVT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 35.04 |
| Open | 33.6 |
| Day High | 35.76 |
| Day Low | 33.22 |
| 52-Week High | 44 |
| 52-Week Low | 14 |
| Volume | 40,118 |
| Average Volume | 50,662 |
| Market Cap | 88.78M |
| PE | -43.49 |
| EPS | -0.78 |
| Moving Average 50 Days | 33.95 |
| Moving Average 200 Days | 31.6 |
| Change | -1.12 |
vTv Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 13, 2026 1:00 PM GMT
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
GlobeNewswire Inc.
Feb 02, 2026 1:00 PM GMT
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment immediately upon execution of the a
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
GlobeNewswire Inc.
Dec 18, 2025 9:05 PM GMT
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2DHIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2